Annals of the Rheumatic Diseases Sparks, J A, Wallace, Z S, Seet, A M, Gianfrancesco, M A, Izadi, Z, Hyrich, K L, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E F, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E L, Duarte-García, A, Valenzuela-Almada, M O, Pons-Estel, G J, Isnardi, C A, Berbotto, G A, Hsu, T Y T, D'Silva, K M, Patel, N J, Kearsley-Fleet, L, Schäfer, M, Ribeiro, S L E, Al Emadi, S, Tidblad, L, Scirè, C A, Raffeiner, B, Thomas, T, Flipo, R M, Avouac, J, Seror, R, Bernardes, M, Cunha, M M, Hasseli, R, Schulze-Koops, H, Müller-Ladner, U, Specker, C, De Souza, V A, Da Mota, L M H, Gomides, A P M, Dieudé, P, Nikiphorou, E, Kronzer, V L, Singh, N, Ugarte-Gil, M F, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J S, Liew, J W, Sirotich, E, Sufka, P, Robinson, P C, Machado, P M & Yazdany, J 2021, ' Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis : Results from the COVID-19 Global Rheumatology Alliance physician registry ', Annals of the rheumatic diseases, vol. 80, no. 9, pp. 1137-1146 . https://doi.org/10.1136/annrheumdis-2021-220418